Background Human papillomaviruses (HPVs) can infect squamous or mucosal epithelia and cause cervical cancer or genital warts. Coinfection with multiple HPV types is a common finding of many epidemiological studies. Therefore, it is necessary to develop a vaccine, which can eradicate established HPV infections and prevent other HPV infections. In this study, we generated chimeric virus like particles (cVLPs) composed of HPV-6b L1, HPV-6b L2 and one artificial HPV-16 mE7 proteins. Methods The artificial HPV-16 mE7 gene was designed by codon modification, point mutation and gene shuffling then chemically synthesized and subcloned behind HPV-6b L2. HPV-6b L1 and L2-mE7 were expressed in insect cells by using Bac-to-Bac system. The generated cVLPs were purified by CsCl gradient ultracentrifuge and analyzed by immunoblot, electron microscope and haemagglutination assay. Results The HPV-6b L1 and L2-mE7 proteins were well expressed in insect cells and could selfassemble into cVLPs, whose diameter was about 55 nm and similar to that of HPV-6b L1/L2 VLPs. Intact cVLPs could be recognized by H6.M48 neutralizing monoclonal antibody and HPV-6b L2 polyclonal antibody, while the denatured cVLPs, but not the intact cVLPs, were reactive to HPV-16 E7 polyclonal antibody. HPV-6b L1/L2-mE7 cVLPs haemagglutinated mouse erythrocytes as efficiently as HPV-6b L1/L2 VLPs did. Conclusions The insertion of the 158 amino acid HPV-16 mE7 protein behind L2 did not disrupt the correct assembling of cVLPs. The morphological characteristics and haemagglutinating activity of cVLPs were similar to those of HPV-6b L1/L2 VLPs. The cVLPs retained conformational B cell epitopes of HPV-6 VLPs and HPV-16 mE7 protein had an internal location in the cVLPs. Therefore, large modified E7 protein with higher immunogenicity could be incorporated into cVLPs by fusing to the C-terminus of L2, which would help to improve the therapeutic effects of L1/L2-E7 cVLPs.
uman papillomaviruses (HPVs) are simple, double strand, DNA viruses that infect squamous or mucosal epithelia and induce a range of epithelial neoplasms, both benign and malignant. HPVs can be divided into two subclasses, low risk and high risk, based on their association with benign lesions or invasive carcinomas, respectively. HPV-16, the most prevalent type of HPVs associated with cervical cancer, causes about 54% of cervical cancer and high grade cervical intraepithelial neoplasia, 1 whereas HPV-6 is associated with the majority of genital warts, for which recurrence is common and treatment is painful and expensive. In addition, coinfection with multiple HPV types is a common finding of many epidemiological studies. Therefore, it is necessary to develop effective prophylactic and therapeutic vaccines against HPVs infection. The shell of HPVs consists of L1 protein (the major capsid protein) and L2 protein (the minor capsid protein). L1 protein alone or together with L2 protein can selfassemble into virus like particles (VLPs) when expressed in eukaryotic or prokaryotic expression systems. Vaccination with papillomavirus VLPs can induce high titres of type specific, neutralizing antibodies (IgG and IgA) and effectively protect animals and humans from papillomaviruses infection. 2 It has been well demonstrated that expression of early protein E7 is required for the maintenance of the proliferative state of HPV infected cells.
3 E7 is considered a tumour specific antigen and can be a target for the immunotherapy of HPV associated cervical malignancies. To develop a vaccine that combines prophylactic and therapeutic properties, some groups have generated L1-E7 or L1/L2-E7 chimeric virus like particles (cVLPs) which can induce neutralizing antibodies directed against L1 virus like particles and E7 specific T cells. 4, 5 However, the forms of E7 in cVLPs were limited to partial length or full length of wild type E7 proteins. 4, 5 To enhance the immunogenicity of cVLPs, we modified the HPV-16 E7 Fig. 1 . Construction of the recombinant plasmids. A: HPV-6b L1N was cloned into the first multicloning site of pFastBacDual under the control of the polyhedron promoter. HPV-16 mE7 was PCR amplified and subcloned behind HPV-6b L2. HPV-6b L2 or the chimeric L2-mE7 construct was subcloned into the second multicloning site under the p10 promoter. B: Sequence alignments of the first 129 nucleotides of HPV-6b L1N and HPV-6b L1wt.
gene by gene shuffling and codon modification and developed HPV-6b L1/L2-mE7 cVLPs to induce stronger E7 specific immune responses and eradicate established infections of HPV-16 than HPV-6b L1/L2-wtE7 cVLPs.
METHODS

Construction of recombinant plasmids
Wild type HPV-6b L1 and L2 genes were obtained from the biopsies of genital warts of Chinese patients as previously described and amplified, whose GenBank accession numbers are AY015006 and AY015008, respectively. 6 To enhance the production of HPV-6b L1, the first 129 nucleotides were modified using overlap PCR and the modified gene was named HPV-6b L1N. The sequence of the first 129 nucleotides of HPV-6b L1N is shown as Fig. 1B . We used the forward overlapping primer 1 (5'-GTGGCCACCGACGCCTACGTGACC AGGACCAACATCTTCTACCACGCCAGCAGCAGCA GGCTGCTGGCCGTGGGACATCCTTATTTTTC-3') and the forward overlapping primer 2 (5'-CGGGATCCCGA CCGCCACCATGTGGAGGCCCAGCGACAGCACCG TGTACGTGCCCCCCCCCAACCCCGTGAGCAAGGT GGTGGCCACCGACGCCTAC-3') and the reverse primer (5'-CGGAATTCCGTTACCTTTTAGTTTTGG CGCGCTTACGTTT-3') to amplify HPV-6b L1N. Restriction enzyme sites are underlined. Then HPV-6b L1N was subcloned into the baculovirus transfer vector pFastBacDual (Invitrogen, USA) under the polyhedral promoter (Fig. 1A) . The full length and stop codon deleted, mutants of HPV-6b L2 were amplified and then subcloned into pFastBacDual vector under the p10 promoter (Fig. 1A) . We designed an artificial HPV-16 E7 gene, named HPV-16 mE7, by codon modification, point mutation and gene shuffling. 7 The mE7 gene was chemically synthesized by Shanghai Sangon Biological Engineering Technology & Services Co. Lid, China, confirmed by sequencing and subcloned behind HPV-6b L2.
Production and purification of chimeric virus like particles
VLPs were produced and purified as previously described. 8 Briefly, sf-9 cells were infected with recombinant baculoviruses at a multiplicity of infection C-terminal of 2 to 5 and cultured in SF-900 II SFM medium (Invitrogen, USA) for 72 hours. Then, the infected cells were collected and sonicated. The clarified lysate was separated by gradient centrifugation. The visible band (at a density of about 1.29 g/ml) was harvested by puncturing tubes on top and on bottom with a 21 gauge needle, dialyzing extensively against 10 mmol/L HEPES (pH 7.2) and quantitated using BCA kit (Pierce, USA).
Immunoblot analysis
Each fraction was analyzed by 8% SDS polyacrylamide gel electrophoresis and Western blot according to standard protocols. Dot blot assay of denatured cVLPs was carried out by boiling the sample for 5 minutes in the presence of dithiothreitol (DTT), while the native cVLPs in PBS were blotted without boiling in the absence of DTT. HPV-6 L2 rabbit antiserum was kindly provided by Dr. Joseph J Carter (Fred Hutchinson Cancer Research Centre, USA) while HPV-16 E7 rabbit antiserum was a gift from MA Zheng-hai (Xinjiang University, Urumqi, China). The H6.M48 and H6.C6 monoclonal antibodies, which bind to intact and denatured HPV-6 VLPs, respectively 9 were kindly given by Prof. Neil D. Christensen (Pennsylvania State University, USA). Goat antirabbit and goat antimouse horseradish peroxidase conjugated antibodies were from Zymed Laboratories (USA). Reaction with HPV specific antibodies was detected using Super Signal West pico trial kit (Pierce, USA).
Electron microscopy
Twenty microtitre samples of fractions from CsCl gradients were dialyzed against 10 mmol/L HEPES (pH 7.2) for 1.5 hours on floating filter pads (0.025 µm pore size, Millipore, USA). The samples were placed onto nitrocellulose carbon grids for 1 minute and washed with 20 drops of water. The grids were then stained with filtered 1% uranyl acetate for 15 seconds. Excess stain was removed and the grids were air-dried. Specimens were examined with a JEM1010 electron microscope at 50 000×magnification.
Haemagglutination assay
The haemagglutination assay was performed as previously described. 10 Erythrocytes were harvested from the citrated blood of C57BL/6 mice, washed three times and resuspended at 1% (v/v) with PBS containing 1 mg bovine serum albumin (BSA)/ml. Two-fold serial dilutions of VLPs in PBS containing 1 mg BSA/ml were performed. The diluted VLPs were mixed with an equal volume of 1% (v/v) erythrocyte suspension. Then, 100 µl of each mixture of erythrocytes and VLPs was transferred to a 96-well plate (Costar, USA), incubated for 3 hours at 4˚C then photographed.
RESULTS
Generation of HPV-6b L1/L2-mE7 cVLPs
Using Bac-to-Bac system, HPV-6b L1N, HPV-6b L2 and HPV-6b L2-mE7 were well expressed in Sf-9 cells. Though inactivation of inhibitory sequences in the first 129 nucleotides of HPV-16 L1 could enhance the expression level of HPV-16 L1 protein in human epithelial cells, 11, 12 the expression level of HPV-6b L1N was not significantly enhanced compared with wt HPV-6b L1 in this study (data not shown). HPV-6b L1/L2 VLPs and HPV-6b L1/L2-mE7 cVLPs were produced and purified by gradient centrifugation. To confirm the presence of L1, L2 and mE7 proteins, purified VLPs and cVLPs were analyzed by Western blot. For HPV-6 L1/L2 VLPs, only antibodies recognizing L1 or L2 reacted with bands about 55 kD or 72 kD, respectively. HPV-6b L1/L2-mE7 cVLPs were positive for all three antibodies ( Fig. 2A ). L2 and mE7 comigrated at 97 kD and the L1 protein contained in the cVLPs was detected as the wt L1 55 kD protein ( Fig. 2A ). There was a minor band (about 45 kD) when HPV-6 L1/L2 VLPs or HPV-6b L1/L2-mE7 cVLPs were incubated with H6.C6. As previously described, 13 the p45 band was present regardless of sample preparation conditions and was a C-terminal truncated form of L1. In addition, when HPV-6b L1/L2 VLPs or HPV-6b L1/L2-mE7 cVLPs were detected by HPV-6b L2 antiserum, there were minor bands below 72 kD or 97 kD, respectively, which may indicate some degradation of the proteins.
Dot blot assay
The dot blot assay showed that intact HPV-6b L1/L2-mE7 cVLPs were recognized by H6.M48 mAb and HPV-6b L2 antiserum and that denatured cVLPs were recognized by HPV-6b L2 and HPV-16 E7 antisera (Fig. 2B) . Since H6.M48 mAb recognized conformationally dependant epitope of intact HPV-6 VLPs, it was suggested that the cVLPs were conformationally indistinguishable from HPV-6b VLPs counterpart. The denatured cVLPs, but not the intact cVLPs, could be recognized by HPV-16 E7 antiserum, which suggested that the mE7 had an internal location in the cVLPs. A similar result was reported by Greenstone et al. 
Electron microscopy
The electron microscopy analysis showed that both HPV-6b L1/L2 VLPs and HPV-6b L1/L2-mE7 cVLPs were about 55 nm in diameter (Figs. 3A and 3B) . Based on the morphological similarity between HPV-6b VLPs and cVLPs, we concluded that insertion of one artificial HPV-16 mE7, composed of 158 amino acids, to the C-terminus of HPV-6b L2 did not disrupt the correct assembling of cVLPs.
Haemagglutination assay
To determine whether the HPV-6b L1/L2-mE7 cVLPs were able to interact with the cellular receptor for papillomaviruses (PVs), we performed a haemagglutination assay to test the binding of cVLPs to mouse erythrocytes. The result showed that cVLPs haemagglutinated mouse erythrocytes and the haemagglutinating activity of cVLPs was similar to that of HPV-6b VLPs (Fig. 3C) , which suggested that cVLPs interacted with the PV receptors on mouse erythrocytes as efficiently as wt HPV-6b VLPs.
DISCUSSION
Based on their structural biology and immunological characteristics, PV VLPs are a good candidate for vehicle to deliver epitopes or genes. 5 PV VLPs were shown to induce strong T-helper responses and the concurrent T-helper responses to the VLPs might enhance the cytotoxic T lymphocytes (CTLs) responses against the antigen fused in the cVLPs. There are two forms of E7 chimeric VLPs, which are L1-E7 cVLPs and L1/L2-E7 cVLPs. In HPV-16 VLPs the ratio of L1 to L2 molecules is about 30:1;
15 that is to say, fusion of an L1-epitope will theoretically result in 360 copies of the epitopes being delivered to the cytosol of an antigen-presenting cell Fig. 3 . Electron micrographs and haemagglutination assay of HPV-6b L1/L2 VLPs and HPV-6b L1/L2-mE7 cVLPs. HPV-6b L1/L2 VLPs (A) and HPV-6b L1/L2-mE7 cVLPs (B) were loaded on nitrocellulose carbon grids, stained with 1% uranyl acetate, and examined with a JEM1010 electron microscope at 50 000×magnification. Bar=100 nm. The haemagglutination assay (C) was performed by two-fold serial dilutions. Diluted HPV-6b L1/L2 VLPs or HPV-6b L1/L2-mE7 cVLPs were mixed with an equal volume of 1% (v/v) erythrocyte suspension. One hundred microlitres of each mixture of erythrocytes and VLPs or cVLPs was loaded to the 96-well plate, incubated for 3 hours at 4˚C and photographed.
(APC), compared to the delivery of 12 copies of the epitopes by an L2-epitopes fusion. However, a maximum of 60 amino acids can be inserted behind a C-terminal truncated L1 without disrupting VLP assembly; 16 the full length wt HPV-16 E7 (98 amino acids) or other modified E7 protein whose size is larger than 60 amino acids cannot be inserted behind a C-terminal truncated L1 to form cVLPs. In addition, L1 is the major capsid protein, and it has been shown that some residues in the L1 protein, such as Asp202, Cys175, and Cys428 of HPV-16 L1, are required for the assemblage of VLPs. There still may be a few other significant residues in L1. Therefore, when some parts of L1 are replaced by large proteins, the efficiency of VLPs assembling is reduced to some extent. 17 Furthermore, Wakabayashi et al 18 showed that the yield of HPV-16 L1ΔC-E7(1-57) cVLPs was 24 times lower than that of HPV-16 L1/L2-E7(1-57) cVLPs and that both types of cVLPs could induce E7 specific cell mediated immunity. L2 is the minor capsid protein and its structure is not as important as L1 for assembling VLPs. Thus, replacing some sequences of L2 by large proteins or fusing large proteins to the C-terminal of L2 may have less influence on the formation of VLPs than L1.
To improve the immune responses induced by incorporating the E7 protein incorporated in cVLPs, we modified the E7 gene as follows. The wt HPV-16 E7 gene was divided into several fragments then rearranged into a defined array with the repeat of some fragments. Then the shuffled E7 gene was further modified by codon modification and point mutation. Thus, the resulting mE7 protein contained nearly two copies of epitopes in wt HPV-16 E7 yet lost the transforming activities. Immunization of mice with mE7 DNA vaccine could induce much stronger E7 specific CTL responses and antitumour effects than with wtE7 DNA vaccine (unpublished data from our laboratory). Similar results were demonstrated by previous studies, [19] [20] [21] which also showed that the artificial shuffled HPV E7 gene had completely lost its transforming properties. Therefore, it is suggested that the HPV-6b L1/L2-mE7 cVLPs will have higher immunogenicity and be much safer than HPV-6b L1/L2-wtE7 cVLPs.
To enhance the yield of our HPV-6b L1/L2-mE7 cVLPs, we modified the first 129 nucleotides of HPV-6b L1. The expression level of wild type L1 in eukaryotic cells is low, which may help the viruses in evading the surveillance of host immune system to some extent. Collier et al 11 and Rollman et al 12 showed that there were inhibitory sequences in the 5' end of the HPV-16 L1 open reading frame and that the expression level could be significantly enhanced when the inhibitory sequences were inactivated. But, in our study, the expression level of HPV-6b L1N was not significantly enhanced compared with wt HPV-6b L1. We think that there may be some differences between the inhibitory sequences in high risk HPVs L1 and low risk HPVs L1.
The result of dot blot assay showed that HPV-6b L1/L2-mE7 cVLPs could be well recognized by H6.M48 mAb, which is a HPV-6 specific, conformation dependent mAb, suggesting that the cVLPs retained conformational B cell epitopes of HPV-6 VLPs and could induce type specific neutralizing antibodies to prevent the infection of HPV-6. The internal location of mE7 in the cVLPs would not affect the induction of E7 specific immune responses because the T cell epitopes could be well presented after uptake of the cVLPs by immunocytes. PV VLPs could bind to a wide variety of cell types through certain molecules. 22, 23 The result of haemagglutination assay demonstrated that cVLPs could interact doneinteract with the papillomavirus receptors on mouse erythrocytes as HPV-6b L1/L2 VLPs, so it was suggested that the cVLPs would be taken up by certain immunocytes as efficiently as VLPs. In addition, results of electron microscopy and haemagglutination assay also showed that the insertion of the 158 amino acids mE7 polypeptides behind L2 did not disrupt assembling of cVLPs, which suggested that large foreign proteins could be encapsidated into cVLPs when they were fused into the C-terminus of L2.
Many epidemiological studies have shown that coinfection with multiple HPV types is very common in humans. The established infection of one type of HPV cannot protect hosts from subsequent infections of other types of HPVs. HPV-16 is the prevalent type of HPVs associated with cervical cancer, whereas HPV-6 is associated with the majority of genital warts. From this study, HPV-6b L1/L2-mE7 cVLPs have the potential to eradicate established HPV-16 infections and prevent further HPV-6b infections. Natural infection with HPV could induce low titres of antibodies against the HPV capsid proteins and the preexisting neutralizing antibodies would reduce the specific cell mediated immune responses induced by cVLPs. 24 Therefore, using heterologous HPV-6b VLPs as vehicle to deliver HPV-16 mE7 protein may be better than HPV-16 VLPs to eradicate the HPV-16 infected cells.
In conclusion, we fused an artificial HPV-16 mE7 protein to the C-terminus of L2 to form cVLPs. The fusion of a 158 amino acid to the C-terminus of L2 does not disrupt the correct assembling of cVLPs. The resulting HPV-6b L1/L2-mE7 cVLPs contain appropriate proteins and are morphologically and conformationally identical to HPV-6b L1/L2 VLPs. Based on the higher immunogenicity of mE7 demonstrated in DNA vaccines research, it is suggested that the mE7 protein incorporated in the cVLPs may induce higher immune responses than wt E7 protein. Therefore, the HPV-6b L1/L2-mE7 cVLPs may be a good candidate for dual purpose vaccines inducing neutralizing antibodies to prevent HPV-6b infection and CTLs that can eradicate established HPV-16 infections. 21 
News China introduce new bird flu measures ahead of spring period
The Chinese Ministry of Agriculture announced new measures to guard against a possible outbreak of bird flu this spring, a time when the bird flu virus is at its most active and contagious.
The ministry called for the compulsory immunization of all domestic poultry to begin before March 15 and to be finished before May. Local veterinary departments have been ordered to ensure poultry raisers keep immunization records. The Ministry of Agriculture is responsible for arranging the production and distribution of bird flu vaccines. The ministry will also send experts to help monitor the breeding of poultry and waterfowl, and intensify monitoring of live poultry markets, border areas and regions where bird flu outbreaks were reported in the past.
China reported 10 outbreaks of bird flu last year. About 47 000 poultry birds died in outbreaks in seven provinces on the Chinese mainland, with another 2.94 million fowls culled, according to figures published by the Ministry of Agriculture last November.
The virus has infected 23 Chinese people since 2003 and killed 14. The latest human case was a 44-year-old farmer in east China's Fujian Province, who was confirmed to be infected with the deadly H5N1 strain of bird flu last week and is still receiving medical treatment in a local hospital.
Fifty-four countries and regions in Asia, Europe and Africa reported outbreaks of bird flu last year.
(Source: Xinhuanet)
